08:39 AM EDT, 09/11/2025 (MT Newswires) -- Maze Therapeutics ( MAZE ) said Thursday its phase 1 study of MZE782, an oral small molecule targeting the solute transporter SLC6A19, demonstrated proof of mechanism and supports advancing to phase 2 trials for the potential treatment of phenylketonuria and chronic kidney disease.

MZE782 produced dose-dependent increases in 24-hour urinary excretion of the neutral amino acids across cohorts, confirming target engagement and SLC6A19 inhibition, the company said.

The treatment was well tolerated with no serious adverse events, and Maze said it expects to start two phase 2 proof of concept trials in 2026.

Maze shares were more than 30% higher in premarket trading.